A new app called Epic Health could monitor glucose levels in healthy and type 2 diabetic patients is just as accurate as traditional, invasive methods that use the finger prick test to draw blood.
Type 2 diabetes cause blood sugar levels to rise, but it must be monitored to prevent people experiencing hyperglycaemia.
The app, which works by the user place a fingertip over the camera lens of their smartphone, has held its first few weeks of pre-clinical trials in Hereford.
The trials are being held to ensure that the app can accurately measure glucose when compared to methods when blood is drawn.
Epic Health was created to help those who suffer from diabetes or even those who are pre-diabetic, by making readings easier.
It was also designed to make blood glucose monitoring less intrusive and more engaging, encouraging users to understand how certain foods affect their body.
Every week 4,500 people are diagnosed with diabetes across the UK, but thousands more are unaware they are at risk.
With current finger-prick tests, a user may have to stab their fingers up to 3,000 times a year.
A pre clinical trial looked at 79 subjects with diagnosed type 2 diabetes, including undiagnosed borderline type 2, and healthy glucose levels took part in the data collection study.
The results showed that 90.58 per cent pairs of results were in the no risk zone and 8.88 per cent of pairs were in the ‘slight lower’ area giving a combined 99.4 per cent safe clinical error result.
The results unequivocally show that a mobile phone application can accurately estimate blood glucose levels of healthy, diagnosed and borderline type 2 users, in a completely non-invasive way.
The application has also proven that healthy subjects can use it to monitor their blood sugar variations after drinking, eating or even exercising, which will encourage keeping a healthy lifestyle.
Dominic Wood, founder and CEO of www.EpicHealth.io said: “We have now validated our technology with private studies and Proof of Concept (POC) trials.
“We report here Part 1 of a study, which involved the monitoring of healthy and diagnosed type 2 participants to test the accuracy of an entirely new non-invasive blood glucose monitoring technology based on a mobile phone application."
Professor Luigi G Martini, Fellow of the Royal Pharmaceutical Society and Professor in Pharmaceutical Innovation, said: “My father lost his battle to diabetes two years ago and I know he had terrible trouble in managing his blood tests.
“This app, if around then, would have made his life so much easier to keep on top of his therapy.”
Dr Richard Wood, Chairman of Bioepic said the result of the second part of the study are set to be announced in two months before a full clinical trial takes place.
“The main difference between the study reported here, and the full clinical trial, is that we will be comparing the clinical accuracy of our app with serum blood values rather than blood taken from the dermal layer of the skin, which often is not the same thing.”
0 التعليقات